GRTS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GRTS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gritstone Bio's Total Assets for the quarter that ended in Mar. 2024 was $137.21 Mil.
During the past 12 months, Gritstone Bio's average Total Assets Growth Rate was 41.70% per year. During the past 3 years, the average Total Assets Growth Rate was 24.90% per year. During the past 5 years, the average Total Assets Growth Rate was 18.60% per year.
During the past 8 years, Gritstone Bio's highest 3-Year average Total Assets Growth Rate was 85.20%. The lowest was 6.70%. And the median was 24.90%.
Total Assets is connected with ROA %. Gritstone Bio's annualized ROA % for the quarter that ended in Mar. 2024 was -102.57%. Total Assets is also linked to Revenue through Asset Turnover. Gritstone Bio's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.
The historical data trend for Gritstone Bio's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gritstone Bio Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Total Assets | Get a 7-Day Free Trial | 184.39 | 221.57 | 278.11 | 240.75 | 177.77 |
Gritstone Bio Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Assets | Get a 7-Day Free Trial | 209.95 | 222.62 | 187.22 | 177.77 | 137.21 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Gritstone Bio's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (A: Dec. 2023 ) | + | Total Liabilities (A: Dec. 2023 ) |
= | 51.85 | + | 125.919 | |
= | 177.77 |
Gritstone Bio's Total Assets for the quarter that ended in Mar. 2024 is calculated as
Total Assets | = | Total Equity (Q: Mar. 2024 ) | + | Total Liabilities (Q: Mar. 2024 ) |
= | 13.964 | + | 123.248 | |
= | 137.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gritstone Bio (NAS:GRTS) Total Assets Explanation
Total Assets is connected with ROA %.
Gritstone Bio's annualized ROA % for the quarter that ended in Mar. 2024 is
ROA % | = | Net Income (Q: Mar. 2024 ) | / | ( (Total Assets (Q: Dec. 2023 ) | + | Total Assets (Q: Mar. 2024 )) | / count ) |
= | -161.54 | / | ( (177.769 | + | 137.212) | / 2 ) | |
= | -161.54 | / | 157.4905 | ||||
= | -102.57 % |
Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Gritstone Bio's Asset Turnover for the quarter that ended in Mar. 2024 is
Asset Turnover | ||||||
= | Revenue (Q: Mar. 2024 ) | / | ( (Total Assets (Q: Dec. 2023 ) | + | Total Assets (Q: Mar. 2024 )) | / count ) |
= | 0.049 | / | ( (177.769 | + | 137.212) | / 2 ) |
= | 0.049 | / | 157.4905 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Gritstone Bio's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Lawrence Corey | director | C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Naiyer Rizvi | director | C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Elaine V Jones | director | C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101 |
Clare Fisher | director | C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Steve E. Krognes | director | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Shefali Agarwal | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Vassiliki Economides | officer: See Remarks | C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Erin Jones | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
James Cho | officer: Chief Accounting Officer | C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608 |
Raphael Rousseau | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Roman Yelensky | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Thomas Woiwode | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Rahsaan Thompson | officer: EVP and General Counsel | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Vijay Yabannavar | officer: See Remarks | C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608 |
Nicholas Simon | director | 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocus Research • 11-08-2023
By Marketwired • 08-09-2023
By Stock market mentor Stock market mentor • 01-18-2023
By sperokesalga sperokesalga • 02-27-2023
By Marketwired • 10-11-2023
By Stock market mentor Stock market mentor • 01-24-2023
By GlobeNewswire GlobeNewswire • 01-18-2023
By sperokesalga sperokesalga • 02-27-2023
By Marketwired • 07-17-2023
By Marketwired • 10-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.